

Literatur:

1. Marks D et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. *Atherosclerosis*. 2003;168:1-14
2. Groselj U et al. Screening in children for familial hypercholesterolaemia: start now. *Eur Heart J*. 2022;43:3209-12
3. Bedlington N et al. The time is now: Achieving FH paediatric screening across Europe - The Prague Declaration. *GMS Health Innov Technol*. 2022;16:Doc04
4. Gidding SS et al. Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. *Eur J Prev Cardiol*. 2022;29:2301-11
5. Luirink IK et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. *N Engl J Med*. 2019;381:1547-56
6. Watts GF et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. *Nat Rev Cardiol*. 2023;20:845-69
7. Wiegman A et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. *Eur Heart J*. 2015;36:2425-37
8. Starr B et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. *Clin Chem Lab Med*. 2008;46:791-803
9. Wald DS and Wald NJ. Integration of child-parent screening and cascade testing for familial hypercholesterolaemia. *J Med Screen*. 2019;26:71-5
10. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Lancet*. 2021;398:1713-25
11. Wald DS and Martin AC. Decision to reject screening for familial hypercholesterolaemia is flawed. *Arch Dis Child*. 2021;106:525-6